Recently, Shanghai WD Pharmac₩✘∑eutical Co., Ltd. (hereinafte®≥ r referred to as WD Pharma✔€∑) and Boehringer Ingelhei✘✔→m China (hereinafter re✘πferred to as Boehringer®↑σ• Ingelheim) jointly announced that Boeh♣Ω↓♠ringer Ingelheim will leverage WD Ph<ε©∑arma's AcuSiS® technolog©↔ y platform to explore innovα™≈ative drug delivery tecπhniques to address the clinicaγπ£l dosing challenges faced by pediat£ ric and geriatric patients,<↔↑ thereby improving medication✔®≤ compliance.
Shanghai WD Pharmaceuti↕&cal Co., Ltd. has recent↑'β ly successfully completed ✔ a randomized, parallel, δ•$double-blind, placebo-controlled, λ♥multi-center Phase II cl¶↓inical trial of WD-1603 (carbidopa¥"/levodopa controlled-rele€₩ase tablets) for the ✔✔↓efficacy and safety in patients with Pa'₹£♦rkinson's disease. The patients with ea∑©∑×rly-stage Parkinson' ₩λs disease were rando♥₹≥mized to receive 4 weeks of treatmenδΩt with WD-1603 25/100 mg (low dose gro∑ε$<up), WD-1603 25/150 mg (medium dose gπ§roup), WD-1603 2x25/100 ✔•↔♠mg (high dose group), or placebo≠φ.
On May 27, 2022, Fudan-Zhangjiang i∞∏<∑ssued an announcement♣§ stating that the company in±★tends to cooperate with WD Phar★✘♣↑ma on WD-1603 and sign related agreeme×$♥nts.
With the approval of the Nat♠₩§ional Medical Products Adminiα$stration, Shanghai WD Pharma is∞₽'β sponsoring a Phase II clinical ≤trial of WD-1603 for the ← treatment of early-onset☆σ idiopathic Parkinson's disease usλ↕'ing "Next-Generat↑♠∑≠ion Carbidopa/Levodopa Controγ&lled-Release Tablets."σγ$≠
On July 12, 2021, WDpharma rec&λ§÷eived the Notice of Appro©↔val for Drug Clinical Trial froφ☆m the National Medical Products ₹ Administration, and the WD≤-1603 project has enε tered into Phase II clinical ®♥£trials.
Shanghai Fudan-Zhangjiang Bi₹©o-Pharmaceutical Co., Ltd. (→↔∞≈hereinafter referred to as &qπ"uot;Fudan-Zhangjiang..★α.
